Methods to mitigate injury from radiation exposure

• US 10,639,296 B2
• Filed: 12/21/2017
• Issued: 05/05/2020
• Est. Priority Date: 10/28/2009
• Status: Active Grant

• Current Assignee: Henry Ford Health System
• Original Assignee: Henry Ford Health System
• Inventors: Kim, Jae Ho, Brown, Stephen L., Kolozsvary, Andrew
• Primary Examiner(s): Olson, Eric
• Application Number:
  US15/850,829
• Publication Number:
  US 20180193307A1
• Time in Patent Office: 866 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/395 having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• CPC Class Codes: A61K 31/4402 only substituted in position 2, e.g. pheniramine, bisacodyl
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/12 Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

Abstract

Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.

Claims

1. A method of mitigating radiation induced injury to a mammal that has been exposed to an external source of radiation, comprising the steps of:

(a) identifying a mammal that has been exposed to an external source of radiation, (b) ascertaining a time of exposure to the external source of radiation, (c) calculating a scheduled administration time by adding a delay period of at least 48 hours to the ascertained time of exposure, and (d) commencing administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal at or after the scheduled administration time, wherein the mammal is not subject to bone marrow transplantation.

2. The method of claim 1 wherein the delay period is at least 72 hours.

3. The method of claim 1 wherein the delay period is at least one week.

4. The method of claim 1 wherein the delay period is between 48 hours and one week.

5. The method of claim 1 wherein the mammal is a human.

6. The method of claim 1 wherein the CXCR4 antagonist is coadministered with a granulocyte colony-stimulating factor.

7. The method of claim 1 wherein the method mitigates radiation induced injury to tissue.

8. The method of claim 1 wherein the method mitigates radiation induced injury to organ tissue.

9. The method of claim 1 wherein the method mitigates radiation induced injury to skin.